Skip to Content
Merck
  • Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue.

Allosteric inhibition of PTP1B activity by selective modification of a non-active site cysteine residue.

Biochemistry (2005-05-25)
Stig K Hansen, Mark T Cancilla, Timothy P Shiau, Jenny Kung, Teresa Chen, Daniel A Erlanson
ABSTRACT

The fluorogenic reagent 4-(aminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole (ABDF) attenuates the functional activity of the protein tyrosine phosphatase PTP1B by reacting selectively with a single cysteine residue, leaving other cysteines in the protein unmodified. This modification reduces Vmax without substantially affecting substrate binding (Km), indicative of an allosteric mode of inhibition. Consistent with this, the cysteine residue modified by ABDF, Cys 121, lies outside the catalytic site but makes interactions with residues that contact His 214, which has been shown to be important for catalysis. Cys 121 is highly conserved among phosphatases, and ABDF also inhibits TC-PTP and LAR. These findings illustrate that targeting cysteine residues outside catalytic sites may be exploited in allosterically regulating enzymes. Moreover, these results suggest a new strategy for inhibiting a promising diabetes target.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
4-Fluoro-7-sulfamoylbenzofurazan
Pricing and availability is not currently available.